Physician profile
Allison E Stephenson
NPI 1962893891
$7,596.82
in general payments reported to CMS, 2019-2025
29 companies · $3,575 in 2025
The $3,575 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $835 · 2024: $3,187 · 2025: $3,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,468 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,467.84 |
| Education | $128.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,685.25 | 2023-2025 | |
| Janssen Biotech, INC. | $777.03 | 2023-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $747.63 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.50 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Celltrion USA INC. | $406.21 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $381.38 | 2023-2025 | Omvoh |
| Genzyme Corporation | $327.57 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $245.36 | 2024-2025 | Tremfya, Stelara, Remicade |
| Intercept Pharmaceuticals, INC. | $229.08 | 2023-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $227.66 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $226.98 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $222.27 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $181.24 | 2024-2025 | Ibsrela |
| Pfizer INC. | $165.86 | 2023-2025 | |
| Celgene Corporation | $161.27 | 2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $161.14 | 2025 | |
| Merck Sharp & Dohme LLC | $157.54 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $138.02 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $123.37 | 2024-2025 | Eohilia, Gattex |
| Madrigal Pharmaceuticals | $94.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $88.76 | 2023-2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $86.76 | 2023 | Rebyota |
| Myriad Women'S Health, INC. | $84.97 | 2023 | Myrisk |
| Vivus LLC | $50.16 | 2024-2025 | Qsymia, Pancreaze |
| Ironwood Pharmaceuticals, INC | $42.71 | 2023 | Linzess |
| Galderma Laboratories, L.P. | $31.68 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $17.12 | 2025 | Suflave |
| Orphalan INC | $14.75 | 2025 | Cuvrior |
| Glaxosmithkline, LLC. | $12.78 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.